This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Heat shock protein 90 (Hsp90)	<p><i>In vitro</i> and mouse studies suggest that levels of secreted Hsp90 could be a biomarker for cancer. In tumor cell lines, malignancy correlated with higher levels of Hsp90 secretion. In human plasma samples, Hsp90 levels were higher in patients with malignant cancers than those in healthy individuals or patients with benign tumors. Next steps could include validating the marker in larger patient populations.</p> <p>At least 14 companies have compounds targeting Hsp90 in clinical and preclinical testing to treat cancer.</p> <p>SciBX 2(48); doi:10.1038/scibx.2009.1755 Published online Dec. 17, 2009</p>	Patent and licensing status unavailable	<p>Wang, X. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Nov. 23, 2009; doi:10.1073/pnas.0908151106</p> <p>Contact: Yongzhang Luo, Tsinghua University, Beijing, China e-mail: yluo@tsinghua.edu.cn</p>